FDA Drug Application (203217) for RISEDRONATE SODIUM by TEVA PHARMS USA

Back to FDA Applications sponsored by TEVA PHARMS USA

Application Number203217
Product Number001
FormTABLET, DELAYED RELEASE;ORAL
Dosage35MG
Product Market Status Prescription
Therapeutic Equivalence Evaluation Code AB Products meeting necessary bioequivalence requirements
Reference Drug
Drug NameRISEDRONATE SODIUM
Active IngredientRISEDRONATE SODIUM



Back to FDA Applications sponsored by TEVA PHARMS USA

Problems, Comments, Suggestions? Click here to contact Greg Thatcher

Please read my Disclaimer





Copyright (c) 2013 Thatcher Development Software, LLC. All rights reserved. No claim to original U.S. Gov't works.